Navigation Links
MAP and Lief Therapeutics Partner to Track Anxiety Real-time in Substance Use Disorder Populations
Date:4/24/2017

MAP Health Management announced today a strategic partnership with Lief Therapeutics designed to recognize elevated anxiety levels in people with addiction who are served by MAP’s patient engagement ecosystem. Lief Therapeutics is the creator of the Lief Smart Patch, a biosensing wearable device that monitors heart and breath rates to identify anxiety levels and can provide biofeedback exercises to aid in reducing anxiety.

The strategic partnership will launch with a pilot program in May of this year wherein 50 individuals currently engaged with MAP and who have a history of anxiety issues will begin using the Lief Smart Patch. MAP will migrate data collected by the patch into its data store, where it will be leveraged to support early relapse identification and care coordination.

The goal of the pilot is to understand how identifying early-onset and elevated anxiety in individuals with Substance Use Disorder can help improve clinical outcomes through enabling better access to care precisely when it is needed. MAP and Lief will present population level findings to various national insurance carriers and health systems to demonstrate how identifying and treating active anxiety within the Substance Use Disorder population has a significant impact on improving clinical outcomes and reducing costs over time.

The patch is worn during the waking hours on the ribcage and syncs with a mobile app for a bi-directional data transfer. Anxiety levels, or even panic attacks, are identified through monitoring various biofeedback indicators such as heart rate variability and breathing patterns. MAP’s alerting technology will allow pre-assigned case managers to reach out to the individual as they are experiencing symptoms of anxiety.

“About 40% of individuals served by MAP have a history of anxiety issues. What’s very clear in our data is that people in recovery from addiction but with untreated anxiety issues tend to have poor outcomes. We believe that elevated anxiety is a leading indicator of a potential return to substance use. The Lief Smart Patch is going to enable us to get actionable data in real-time to change the trajectory and affect a better outcome,” said Jacob Levenson, CEO of MAP Health Management, LLC.

“Anxiety and stress affect every aspect of a patient's life and care cycle. We're excited to provide patients and doctors with a tool that tracks and improves symptoms of stress in-the-moment, helping intervene with patients when they need it most. This initiative with MAP is a big step in the right direction – empowering patients with data-driven, cost-effective preventative measures,” said Rohan Dixit, CEO of Lief Therapeutics.

The Lief Therapeutics strategic partnership is the fourth announced by MAP in recent months as MAP continues to expand its robust ecosystem of patients, providers, insurance companies, and technology products, all of which are integrated into MAP’s population health platform. MAP is generally recognized as having the most robust risk identification and data reporting environment related to addiction in the country.

About MAP Health Management, LLC
MAP delivers technology-enabled solutions, including telehealth and other remote engagement devices and applications, that improve clinical and financial outcomes for chronic behavioral health disorders such as Substance Use Disorder. MAP’s robust ecosystem of solutions empowers treatment providers, health insurance companies, health systems, and patients with the right data at the right time to improve clinical and financial outcomes. For more information, visit https://www.thisismap.com.

About Lief Therapeutics
Lief Therapeutics offers a break-through wearable sensor for stress and anxiety management to consumers, patients, healthcare providers and health systems. Lief is accompanied by an 8-week digital anxiety intervention course designed in collaboration with Stanford and UCSF clinicians, and integrates with a variety of common EMR and health record systems. To learn more about Lief Therapeutics, please visit https://www.getlief.com.

Read the full story at http://www.prweb.com/releases/2017/04/prweb14267540.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Just Biotherapeutics, Inc., Hangzhou Just Biotherapeutics, Ltd., and G-CON Manufacturing, Inc. Announce Collaboration on State of the Art Bioprocess Facility in China
2. Prof. Nishimura to Present Emerging Technologies for Evaluation of Biotherapeutics at Pittcon 2017 JAIMA Symposium
3. The Challenges and Opportunities for Cannabis-Based Therapeutics: Catalent to Present at Upcoming Industry Conference
4. T3D Therapeutics Receives FDA Approval for a 6-Month, Open-Label Extension to its Phase 2a Trial of T3D-959 for Treatment of Mild to Moderate Alzheimer’s Disease
5. ITeos Therapeutics Announces Appointment of Dr. Alain Thibault as Chief Medical Officer
6. Stem Cell Pioneer, Celltex Therapeutics, Announces Sponsorship of Regenera Global Conference
7. Gemstone Biotherapeutics Licenses Additional Johns Hopkins Wound Care Technology
8. Digital Therapeutics Pioneer Pear Therapeutics Raises $20M
9. Catalent Biologics and Cerenis Therapeutics Announce Phase III Trial of CER-001 in Europe and North America Leveraging GPEx® Cell Line Technology
10. iTeos Therapeutics Enters Into Therapeutic Antibody Discovery Partnership with Adimab
11. Jupiter Orphan Therapeutics, Inc. Enters into a Global Licensing Agreement with Murdoch Childrens Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... 24, 2017 , ... The 2017 NCSL International Workshop & ... focuses on the new ISO/IEC 17025 standards. This marks the first time in ... calibration will be changed. , As an exhibitor, METTLER TOLEDO will showcase ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... solution focused on delivering end-to-end sleep health care at scale, indicates record-breaking ... shows that adherence rates for positive airway pressure (PAP) therapy, the most widely ...
(Date:7/24/2017)... ... July 24, 2017 , ... A Southern California-based author has released ... abuse, and how she has overcome them. “Forbidden Memories: A Memoir,” by author Michelle ... how she has risen above. , In “Memories,” readers get a firsthand look at ...
(Date:7/24/2017)... ... July 24, 2017 , ... Committed to eliminating clubfoot as ... 100,000 children in their treatment program. Clubfoot is a pervasive problem in the ... is limited or non-existent. Without intervention, these children are destined to grow up ...
(Date:7/24/2017)... ... July 24, 2017 , ... Clinical Quality Assurance:, Roles and ... 22-23, 2017 – Arlington, VA, http://www.fdanews.com/cqa , Early bird pricing for ... growing demands to track and report adverse events place even greater pressure on ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... , July 14, 2017 Endo International plc (NASDAQ: ... on Tuesday, August 8, 2017.  Members of its senior management team ... markets open at 8:30 a.m. ET. The dial-in ... (866) 497-0462, International (678) 509-7598, and the passcode is 45397076. Please ... A replay of the call ...
(Date:7/12/2017)... July 12, 2017 CarpalAID is a revolutionary new product ... surgery. Carpal tunnel syndrome affects more than 8 million ... the rate of men. The common methods of treating CTS are ... uncomfortable hand braces or gloves. ... CarpalAID is a clear patch worn on ...
(Date:7/11/2017)... LINCOLNSHIRE, Ill. , July 11, 2017 /PRNewswire/ ... hematology and urinalysis diagnostic testing equipment as well ... latest innovation: a way to make quality assurance ... control processes. "Sysmex is well known for the ... SM Quality Monitor elevates quality assurance processes ...
Breaking Medicine Technology: